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ABSTRACT
the AUC0–last values were lower by 35% and 70%, respectively. In
KO mice, AJ coadministration reduced oral fexofenadine Cmax and
AUC0–last values by 67% and 59%, respectively, while GFJ had no
effects. Intravenous and oral rosuvastatin pharmacokinetics were
similar among WT and KO mice. We conclude that intestinal
OATP2B1 is a determinant of oral fexofenadine absorption, as well
as a target for fruit juice interactions. OATP2B1 does not significantly influence rosuvastatin disposition in mice.

Introduction

et al., 2002; Grube et al., 2006; Niessen et al., 2009; Seki et al., 2009;
Knauer et al., 2010; Hussner et al., 2015; Kim et al., 2017; Nakano et al.,
2019). However, in vitro studies have since shown OATP2B1 has
remarkably broad substrate specificity ranging from molecules that
are small (5-aminosalicylate), large (bromosulfophthalein), peptidic
(substance P), hydrophilic (benzylpenicillin), lipophilic (amiodarone),
uncharged (abiraterone), anionic (rosuvastatin), cationic (celiprolol), or
zwitterionic (fexofenadine) (Tirona and Kim, 2014). Given its expression in key tissues of drug disposition and its diversity of substrates,
OATP2B1 is thought to play at role in the pharmacokinetics of many
drugs.
Perhaps the most influential support for the contribution of OATP2B1
in drug disposition comes from results of clinical food-drug and drugdrug interaction studies. The first and prototypical example is the fruit
juice/fexofenadine interaction (Dresser et al., 2002). Fexofenadine is a

Organic anion transporting polypeptide (OATP) 2B1 was discovered
almost two decades ago and originally characterized as a membrane
transporter with broad tissue distribution and relatively narrow substrate
specificity (Tamai et al., 2000; Kullak-Ublick et al., 2001). Indeed,
OATP2B1 is expressed in brain, liver, kidney, heart, lung, placenta,
small intestine, skeletal muscle, pancreas, coronary artery, platelets, and
macrophages (Tamai et al., 2000; Kullak-Ublick et al., 2001; St-Pierre
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SIGNIFICANCE STATEMENT
A novel mouse model with targeted disruption of the Slco2b1
gene revealed that OATP2B1 is a determinant of oral absorption
but not systemic disposition of fexofenadine, as well as a target of
fruit juice interactions. Rosuvastatin oral and intravenous pharmacokinetics were not dependent on OATP2B1. These findings
support the utility of the Slco2b1 KO mouse model for defining
mechanisms of drug disposition at the intersection of in vitro and
clinical pharmacology.

ABBREVIATIONS: AJ, apple juice; AUC0–‘, area under the concentration-time curve from time zero to infinity; AUC0–last, area under the
concentration-time curve from time zero to the last sampling time; BCRP, Breast Cancer Resistance Protein; CLplasma, plasma clearance; GFJ,
grapefruit juice; HEK293, human embryonic kidney 293; HEK293T, human embryonic kidney 293 type T; KO, knockout; KOMP, Knockout Mouse
Project; LC-MS/MS, liquid chromatography–tandem mass spectrometry; MDCKII, Madin-Darby canine kidney type II; mOATP, mouse organic
anion transporting polypeptide; mOCT, mouse organic cation transporter; mPMAT, mouse plasma membrane monoamine transporter; m/z, massto-charge ratio; OATP, organic anion transporting polypeptide; OCT, organic cation transporter; rOATP, rat organic anion transporting polypeptide;
Tmax, time to maximum plasma concentration; t1/2, terminal half-life; WT, wild type.
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Organic anion transporting polypeptide 2B1 (OATP2B1) is a widely
expressed membrane transporter with diverse substrate specificity.
In vitro and clinical studies suggest a role for intestinal OATP2B1 in
the oral absorption of medications. Moreover, OATP2B1 is highly
expressed in hepatocytes where it is thought to promote liver drug
clearance. However, until now, a shortcoming of studies implicating
OATP2B1 in drug disposition has been a lack of in vivo models. Here, we
report the development of a knockout (KO) mouse model with targeted,
global disruption of the Slco2b1 gene to examine the disposition of
two confirmed mOATP2B1 substrates, namely, fexofenadine and
rosuvastatin. The plasma pharmacokinetics of intravenously administered fexofenadine was not different between KO and wildtype (WT) mice. However, after oral fexofenadine administration,
KO mice had 70% and 41% lower maximal plasma concentration
(Cmax) and area under the plasma concentration-time curve (AUC0–last)
than WT mice, respectively. In WT mice, coadministration of
fexofenadine with grapefruit juice (GFJ) or apple juice (AJ) was
associated with reduced Cmax by 80% and 88%, respectively, while

OATP2B1 in Fexofenadine and Rosuvastatin Disposition

Materials and Methods
Reagents
[3H]-fexofenadine (78 Ci/mmol, 99.7% radiochemical purity) was custom
synthesized by Quotient Bioresearch (Fordham, Cambridgeshire, UK) by

nonspecific labeling. [3H]-rosuvastatin (5 mCi/mmol, 99% radiochemical purity)
was purchased from American Radiolabeled Chemicals (St. Louis, MO). [3H]bromosulfophthalein (10.6 Ci/mmol, 99.5% radiochemical purity) was obtained
from Moravek (Brea, CA). [3H]-estrone-3-sulfate (54.3 Ci/mmol, .97% radiochemical purity) was purchased from PerkinElmer (Woodbridge, ON, Canada).
Unlabeled fexofenadine, d6-fexofenadine, rosuvastatin, and d6-rosuvastatin were
purchased from Toronto Research Chemicals (Toronto, ON). Concentrated (4)
GFJ (Minute Maid, 100% grapefruit juice frozen concentrate) and concentrated
(4) AJ (no name, apple juice, frozen concentrate) were acquired from
Walmart (London, ON) and Real Canadian Superstore (London, ON),
respectively. The same GFJ and AJ stocks were used for all fruit juice
experiments. All other chemicals, unless otherwise stated, were obtained from
Sigma-Aldrich (St. Louis, MO).
Plasmids
Expression plasmids in pCMV6 vector for mOATP2B1 (NM_001252530) and
mOATP1A5 (NM_130861) were obtained from Origene (Rockville, MD).
Employing polymerase chain reaction with the Expand Long Template Polymerase Chain Reaction System (Roche Applied Science, Indianapolis, IN), other
expression plasmids for mOATP1A1, mOATP1A4, mOATP1A6, mouse organic
cation transporter (mOCT) 1, mOCT3, and mouse plasma membrane monoamine
transporter (mPMAT) were developed by amplification of open reading frame
cDNA from mouse small intestine, liver, or kidney cDNA (BioChain Institute,
Inc., Newark, CA) using the following primers:
mOATP1A1 (forward) 59-ACCATGGAAGAAACAGAGAAAAAGGTTGC-39
and (reverse) 59-TTACAGCTTAGTTTTCAGTTCTCCATCG-39;
mOATP1A4 (forward) 59-GTTCAAAGAATAGACATTTGGAGACAATC-39
and (reverse) 59-AAACTAGTGACATGTGCGTTCTGGTTC-39;
mOATP1A6 (forward) 59-AAGAACAAAATGGGAGAACCTGGGAAA-39
and (reverse) 59-GAAACCTCATTACAGCTTAGTTTTCAG-39;
mOCT1 (forward) 59-TACCCAGCCATGCCCACCGTGGACGAT-39
and (reverse) 59-GCATCCCTGTCAGGTATGTGGGGATTT-39;
mOCT3 (forward) 59-GGGCGCACCATGCCCACGTTCGACCAGGCA-39
and (reverse) 59-ACAGGGGCCTCAGACATCAGAAGTAGAAAC-39;
mPMAT (forward) 59-TGAACTGCCATGGGCTCTATCGGAAGCCAG-39
and (reverse) 59-CCCGGCTCAGGGACCGACAGGGATGGAGTC-39
The resulting amplicons were cloned into either pEF6/V5-His-TOPO or
pcDNA3.1/V5-His-TOPO expression plasmids (Invitrogen, Burlington, ON).
Transient Expression of Mouse Drug Transporters in Cultured Cells
HeLa and human embryonic kidney 293 (HEK293) type T (HEK293T) cells
were purchased from American Type Culture Collection (Manassas, VA) for use
in transient transfection studies. HeLa and HEK293T cells were cultured in
Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific, Grand Island,
NY) supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 2 mM L-glutamine (Invitrogen), at 37C and 5% CO2. For transport
experiments, HeLa cells were seeded on regular 12-well plates (2.5  105
cells/well), while HEK293T were seeded on poly-L-lysine–coated 12-well plates
(4.0  105 cells/well). After 48 hours, cells were transfected with blank insert
expression plasmids (control) or expression plasmids containing transporter
cDNA inserts (1 mg DNA/well) using Lipofectamine 3000 (Invitrogen) in OptiMEM (Thermo Fisher Scientific) for HEK293T cells or according to our
previously described method (Cvetkovic et al., 1999) for HeLa cells. Cells were
incubated for 16 hours prior to transport experiments.
Stable Expression of Mouse OATP2B1 in Cultured Cells
Madin-Darby canine kidney type II (MDCKII) cells were cultured in
Dulbecco’s modified Eagle’s medium, 10% FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine and transfected with pCMV6-mOATP2B1
expression plasmid using Lipofectamine 3000. Cell clones were obtained by a
dilution method in 96-well plates under selection with geneticin (800 mg/ml;
Invitrogen). The clone with the highest transport activity toward [3H]-estrone
sulfate (hereafter, referred to as MDCKII-mOATP2B1) was expanded and
maintained in geneticin selection media. For transport experiments, MDCKIIcontrol and MDCKII-mOATP2B1 cells were grown on 12-well plates (seeding
density of 7.5  105 cells/well). After 48 hours, medium was replaced with that
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nonmetabolized, zwitterionic antihistamine that is remarkably well
absorbed after oral administration (bioavailability of 30%). When
taken with grapefruit juice (GFJ), orange juice, or apple juice (AJ),
fexofenadine plasma concentrations are dramatically reduced by
70%–80%, with the strongest effects seen with AJ (Dresser et al.,
2002). For GFJ, the major flavonoid, naringin, is the main constituent
involved in the fexofenadine interaction (Bailey et al., 2007). Subsequent studies have found that absorption of other non- or poorly
metabolized drugs such as talinolol (Schwarz et al., 2005), celiprolol
(Lilja et al., 2003), atenolol (Jeon et al., 2013), aliskiren (Tapaninen
et al., 2011) elvitegravir (Yonemura et al., 2018), and levothyroxine
(Lilja et al., 2005) are also reduced when taken with fruit juices. The
mechanism of fruit juice interactions with nonmetabolized drugs originally
focused on OATP1A2 (Dresser et al., 2002), but many investigators are
unable to consistently demonstrate that OATP1A2 is expressed in the
gastrointestinal tract (Drozdzik et al., 2014). Therefore, attention has turned
to OATP2B1 as the potential target of fruit juice/drug interactions since it
is expressed in the small intestine, transports affected drugs including
fexofenadine (Nozawa et al., 2004), and its transport activity is inhibited by
fruit juice constituents in vitro (Satoh et al., 2005; Shirasaka et al., 2013).
With respect to clinical drug-drug interactions, intestinal OATP2B1 has
been implicated in the 50% reduction in bioavailability of oral rosuvastatin
when coadministered with the OATP2B1 inhibitor ronacaleret (Johnson
et al., 2017). Rosuvastatin is a poorly metabolized, hydrophilic drug whose
disposition is influenced by hepatic OATP1B1/OATP1B3 and the
intestine/liver efflux transporter Breast Cancer Resistance Protein
(BCRP, also ABCG2). Since experiments showed that neither
OATP1B1/OATP1B3 nor BCRP were relevant to the ronacaleret
interaction, it was concluded that rosuvastatin oral absorption is dependent
on intestinal OATP2B1 (Johnson et al., 2017).
While there is growing evidence to support OATP2B1 as a clinically
relevant drug transporter, there are several examples of in vitro/clinical
disconnects that challenge this notion. For instance, there are some
poorly metabolized OATP2B1 substrates such as rosuvastatin and
pravastatin that are not subject to significantly reduced oral absorption
when taken together with fruit juices in clinical studies (Lilja et al., 1999;
Kashihara et al., 2017). Additionally, a recent study showed that the
major clinical drug interaction between atenolol and apple juice is not
related to OATP2B1 since the drug is not a substrate and osmolarity may
be a contributing factor (Funai et al., 2019). Another potentially
disconcerting observation are reports that show that OATP2B1 is
localized to the basolateral (Mooij et al., 2016; Keiser et al., 2017)
rather than the apical (luminal) membrane of enterocytes (Kobayashi
et al., 2003), casting doubt on a role in oral drug absorption and fooddrug interactions.
For the most part, the current concept of a possible link between
OATP2B1 and its functions in pharmacokinetics has relied on associations between in vitro transporter pharmacology and tissue expression
with clinical observations. A significant shortcoming of OATP2B1
pharmacology studies has been, until now, the lack of in vivo models that
could be applied to expose mechanisms at the systems level. Here, we
report the development of a mouse model with disruption of the gene
encoding OATP2B1 (Slco2b1). We found that mouse OATP (mOATP)
2B1 affects the disposition of fexofenadine but not rosuvastatin.
Furthermore, we show that mOATP2B1 is a target for fruit
juice/fexofenadine pharmacokinetic interactions in vivo.
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containing sodium butyrate (25 mM) to increase transporter gene expression.
Cells were then maintained for 24 hours prior to transport experiments.
Immunofluoresence Microscopy of Cultured Cells and Liver

Western Blot Analysis
Cell and tissue homogenates were prepared in Pierce IP Lysis Buffer
(ThermoFisher) and proteins (50 mg/well) were separated by SDS-PAGE using
4%–12% gradient gels (NuPage; Invitrogen). After transfer to polyvinylidene
difluoride membranes, blots were probed with custom rabbit polyclonal
antibodies against mouse OATP2B1 (Invitrogen), glyceraldehyde-3-phosphate
dehydrogenase (Abcam, Cambridge, MA), or actin (Santa Cruz, Dallas, TX) and
visualized using horseradish peroxidase–labeled anti-rabbit antibodies (Cell
Signaling, Danvers, MA) and chemiluminescence (Amersham ECL Select;
GE Healthcare, Mississauga, ON) on an ImageQuant LAS 500 instrument (GE
Healthcare).
Solute Transport by Mouse Drug Transporters In Vitro
Control and transporter-transfected MDCKII and HeLa cells were plated
onto 12-well culture plates for solute uptake experiments. [3H]-fexofenadine,
[3H]-rosuvastatin, [3H]-bromosulfophthalein, [3H]-estrone-3-sulfate, and/or unlabeled fexofenadine or rosuvastatin were dissolved in Krebs-Henseleit buffer
(1.2 mM MgSO4•7H2O, 0.96 mM KH2PO4, 4.83 mM KCl, 118 mM NaCl,
1.53 mM CaCl2•2H2O, 23.8 mM NaHCO3, 12.5 mM 4-[2-hydroxyethyl]-1piperazineethanesulfonic acid, and 5 mM glucose in water) at pH 6 with the
exception of experiments with mouse organic cation transporter (OCT) 1 and
OCT3 transporters, where pH 7.5 was used. In the context of OATP2B1, previous
reports have demonstrated substrate-dependent stimulation of transporter activity
by acidic extracellular milieu (Kobayashi et al., 2003; Nozawa et al., 2004;
Visentin et al., 2012). The drug dose (400 ml) was applied to cultured cells for
5–10 minutes at 37C and 5% CO2. Thereafter, cells were washed three times
rapidly with ice-cold PBS. To quantify cellular radioactive drug accumulation,
cells were lysed using 1 ml of 1% SDS in water (v/v) and intracellular radioactivity
was measured by liquid scintillation spectrometry (Tri-Carb 3900TR; Perkin
Elmer, Waltham, MA). For the experiments with unlabeled fexofenadine or
rosuvastatin, the cells were lysed using 400 ml of acetonitrile spiked with internal
standard d6-fexofenadine (10 ng/ml) or d6-rosuvastatin (20 ng/ml). Cell lysates
were centrifuged for 10 minutes at 13,500 rpm in a microcentrifuge and
supernatants were dried in a SpeedVac (ThermoFisher) at 45C. Residues were
analyzed for fexofenadine or rosuvastatin by the liquid chromatography–tandem
mass spectrometry (LC-MS/MS) methods described subsequently. For studies in
MDCKII cells, transport activity in each well was corrected for protein content as
determined by the Pierce BCA Protein Assay Kit (ThermoFisher).
Targeted Disruption in OATP2B1 in Mice
Slco2b1tm1a(KOMP)Wtsi mice were generated in collaboration with the Knockout
Mouse Project (KOMP) at University of California, Davis (Davis, CA). National
Institutes of Health grants to Velocigene at Regeneron Inc. (U01HG004085) and
the CSD Consortium (U01HG004080) funded the generation of gene-targeted

Gene Expression Analysis of Mouse Tissues
Tissues from WT and OATP2B1 KO mice were harvested after isoflurane
overdose and RNA was extracted using TRIzol (Life Technologies). For small
intestine, mucosal samples were collected while whole organ was processed for
liver, kidney, brain, and lung. Complementary DNA was obtained by reverse
transcription (Multiscribe; Applied Biosystems) with random hexamers. Relative
mRNA expression of transporter genes was determined by SYBR Green–based
quantitative polymerase chain reaction (7500 system; Applied Biosystems) with
normalization to 18S ribosomal RNA by TaqMan reagents (Applied Biosystems).
The primer sequences can be found in Supplemental Table 2.
Fexofenadine Pharmacokinetics in WT and OATP2B1 KO Mice
Male (adult, age-matched, 10–31 weeks old) WT and KO mice were used. For
intravenous pharmacokinetic studies, fexofenadine (1 mg/kg) was dissolved in
saline and administered via tail vein. Serial blood samples (;20 ml each) from
each mouse were collected from the saphenous vein at 5, 15, and 30 minutes and
1 and 2 hours post drug administration in heparinized microcentrifuge tubes. For
oral drug administration, animals were fasted for 4 hours prior to drug
administration. Fexofenadine (1 mg/kg) dissolved in 200 ml of either PBS (pH
3.5, which is equivalent to GFJ and AJ vehicles, 290 mOsm/kg), 4 concentrated
GFJ (2464 mOsm/kg), or 4 concentrated AJ (2794 mOsm/kg), was administered
by oral gavage. Serial blood samples (;20 ml each) were obtained from each
mouse via the saphenous vein at 5, 15, and 30 minutes and 1, 2, and 3 hours
post drug administration in heparinized microcentrifuge tubes. Blood samples
were centrifuged at 5000g for 10 minutes at 4C. Resulting plasma was stored
at 280C until fexofenadine was measured by LC-MS/MS. This animal study
protocol was approved by the Animal Use Subcommittee of the University of
Western Ontario.
Rosuvastatin Pharmacokinetics in WT and OATP2B1 KO Mice
Male WT and KO mice between 8 and 16 weeks of age were used for the
experiments. Animals were administered 1 mg/kg rosuvastatin in saline (,2%
dimethylsulfoxide) by tail vein injection or 10 mg/kg rosuvastatin by oral gavage
in 0.5% hydroxypropylmethylcellulose. All blood samples (;20 ml each) were
collected by serial sampling from each mouse at 10, 20, and 30 minutes and 1, 2, 4,
and 8 hours after oral dosing and 5, 15, and 30 minutes and 1, 2, 4, and 6 hours
following intravenous dosing. Blood was collected with a heparinized pipet after
saphenous or tail vein puncture and centrifuged at 12,000g for 5 minutes to obtain
plasma. All plasma and tissue samples were stored at 280C until analysis by
LC-MS/MS. The study protocol was approved by the Animal Use Subcommittee
of the University of Western Ontario.
Liquid Chromatography–Tandem Mass Spectrometry
Fexofenadine Assay. Plasma samples (5 ml) were spiked with internal
standard (d6-fexofenadine, 5 ml, 200 ng/ml), precipitated with acetonitrile (15 ml)
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Cellular expression and localization of mOATP2B1 in MDCKII cells and
mouse liver was determined by immunofluorescence microscopy. For cells, MDCKIIcontrol and MDCKII-mOATP2B1 were cultured on Falcon four-chamber glass
culture slides (ThermoFisher Scientific). After fixation with 4% paraformaldehyde,
cells were permeabilized in 0.3% Triton X-100 in PBS and then blocked with 2%
bovine serum albumin in PBS. Formalin-fixed, paraffin-imbedded mouse livers were
dewaxed in xylene and graded ethanol solutions and then rehydrated in water. Antigen
retrieval occurred in Tris-EDTA buffer (pH 9) with boiling in a microwave for
20 minutes. Tissue was blocked with 2% bovine serum albumin in PBS. Prepared
tissues and cells were then incubated with custom-made, polyclonal, rabbit
mOATP2B1 antibodies that were developed (Invitrogen) using the protein
peptide sequence near the N-terminus (MGTEDMHERKVSVEPQD), which
is present in both major mOATP2B1 protein variants (NP_001239459 and
NP_780525). Anti-rabbit Alexa Fluor 488 (Invitrogen) secondary antibodies
were applied and slides were mounted with VECTASHIELD containing nuclear 49,6diamidino-2-phenylindole stain (Vector Laboratories, Burlingame, CA). Epifluorescence
microscopy was performed on a Nikon Eclipse 80i instrument.

embryonic stem cells for 8500 genes in the KOMP Program, which were archived
and distributed by the KOMP Repository at University of California, Davis, and
Children’s Hospital Oakland Research Institute (Oakland, CA; U42RR024244).
For more information or to obtain KOMP products, the reader is referred to
www.komp.org. In this mouse model, a gene trap cassette was inserted into the
Slco2b1 gene in intron 3 of C57BL/6J mice by homologous recombination in
embryonic stem cells to produce global knockdown of OATP2B1 gene
expression. As shown in Results, OATP2B1 was undetectable in all tissues
examined; therefore, for the purpose of this report we will refer to the homozygous
Slco2b1tm1a(KOMP)Wtsi mice as OATP2B1 knockout (KO) mice, i.e., mice with
targeted disruption of Slco2b1. Wild-type (WT) C57BL/6 mice (Jackson
Laboratories, Bar Harbor, MA) and KO mice were housed in a specific
pathogen-free barrier facility in a temperature-controlled environment with a
12-hour light/dark cycle and received a standard diet (2018 Teklad Global 18%
protein rodent diet; Harlan Laboratories, Madison, WI) and water ad libitum. For
genotyping, DNA was extracted from whole blood or liver using the MagNA Pure
system (Roche Diagnostics, Laval, QC, Canada). Diagnostic DNA amplifications
were performed using polymerase chain reaction (AmpliTaq Gold polymerase;
Applied Biosystems, Carlsbad, CA). The primer sequences can be found in
Supplemental Table 1.

OATP2B1 in Fexofenadine and Rosuvastatin Disposition

Pharmacokinetic Calculations
Pharmacokinetic analysis was performed using noncompartmental methods. The area under the concentration-time curve from time zero to the last
sampling time (AUC0–last) was calculated using the linear trapezoid method.
The area under the concentration-time curve from time zero to infinity
(AUC0–‘) was calculated as the sum of AUC0–last and Clast/k, where Clast is the
last sampled concentration and k is the elimination rate constant obtained
from the regressed slope of ln-transformed terminal concentrations. The
terminal half-life (t1/2) was determined from ln2/k. The maximal plasma
concentration (Cmax) and the time to maximum plasma concentration (Tmax)
values were obtained directly from the observed results. Plasma clearance
(CLplasma) was calculated as intravenous dose divided by AUC0–‘. Mean
residence time was calculated as the area under the first moment (C  t) curve
divided by AUC0–‘. The volume of distribution at steady state was calculated
as the product of the mean residence time and CLplasma. Bioavailability was
calculated as AUC0–‘,oral/AUC0–‘,intravenous  Doseintravenous/Doseoral.
Statistics
The unpaired two-tailed Student’s t test was used to determine statistical
differences between groups. Statistical significance was deemed at P ,
0.05. All statistical analyses were conducted using GraphPad Prism (La
Jolla, CA).

Results
Mouse OATP2B1 Transport Activity toward Prototypical
Substrates. An MDCKII cell line stably expressing mOATP2B1 was
developed to characterize solute transport activity. Immunofluorescence

imaging demonstrated that mOATP2B1 was localized largely on the
plasma membrane of MDCKII-mOATP2B1 cells grown as a monolayer
on plastic dishes (Fig. 1A), while immunoblot analysis confirmed
heterologous expression of mOATP2B1 (Fig. 1B). Next, the uptake of
previously reported human OATP2B1 substrates, estrone sulfate (Tamai
et al., 2000), dehydroepiandrosterone sulfate (Kullak-Ublick et al.,
2001), and bromosulfophthalein (Kullak-Ublick et al., 2001), was
evaluated in the MDCKII-mOATP2B1 cell line. In comparison with the
MDCKII-control cells, estrone sulfate, dehydroepiandrosterone sulfate,
and bromosulfophthalein uptake values were 2.8-, 1.8-, and 3.5-fold
greater in the MDCKII-mOATP2B1 cells (Fig. 1C), respectively.
The bile acid taurocholate has been reported to be a substrate of
human OATP2B1 in some studies (Nozawa et al., 2004), but not
others (Kullak-Ublick et al., 2001; Knauer et al., 2013). We found
that taurocholate uptake was 2.5-fold greater in MDCKII cells
expressing mOATP2B1 compared with control cells (Fig. 1C),
indicating that mOATP2B1 is a bile acid transporter. These results
demonstrate that mouse and human OATP2B1 have generally
similar substrate specificities.
Fexofenadine Transport by Mouse OATP2B1. Fexofenadine was
found to be a human OATP2B1 substrate in studies with transfected
HEK293 (Nozawa et al., 2004) and MDCKII cells (Ming et al., 2011)
and in the Xenopus laevis oocyte model (Shirasaka et al., 2014), but not
by others using OATP2B1-expressing HEK293 (Shimizu et al., 2005) or
HeLa (Glaeser et al., 2007) cells. In previous studies with fexofenadine,
acidic extracellular pH enhanced OATP2B1-mediated cellular uptake
(Nozawa et al., 2004); therefore, we performed experiments for
mOATP2B1 in uptake media adjusted to pH 6. We observed that [3H]fexofenadine uptake was 1.25-fold greater in HeLa cells transiently
transfected with mOATP2B1 compared with vector control–transfected
cells (Fig. 1D). Furthermore, unlabeled fexofenadine accumulated at
1.8-fold higher levels in the MDCKII-mOATP2B1 cell line compared
with MDCKII-control cells (Fig. 1D). Concentration dependency for
fexofenadine uptake (0.1–300 mM) was studied in MDCKII-control and
MDCKII-mOATP2B1 cells. The mOATP2B1-mediated fexofenadine
uptake appeared concentration dependent, with loss of linearity more
evident at the highest concentration examined (Fig. 1E). Evaluation of
kinetics by Eadie-Hofstee plot analysis (V/S vs. V) (Fig. 1E) did not
expose multiple binding sites for mOATP2B1 that were previously
observed for fexofenadine and human OATP2B1 (Shirasaka et al.,
2014). Solubility precluded the ability to study higher fexofenadine
concentrations than 300 mM, and hence we were not able to estimate
kinetic parameters KM and Vmax. Finally, we found that mOATP2B1mediated cellular bromosulfophthalein uptake in the MDCKII model
was inhibited by 57% in the presence of the known potent human
OATP2B1 inhibitor/substrate, erlotinib (10 mM) (Johnston et al.,
2014; Bauer et al., 2018) and by 33% with fexofenadine (300 mM)
(Fig. 1F). Taken together, these results show that fexofenadine is a
substrate for mOATP2B1.
Rosuvastatin Transport by Mouse OATP2B1. Human OATP2B1,
including both its major intestinal and hepatic protein variants, has been
shown to transport rosuvastatin (Ho et al., 2006; Knauer et al., 2013).
Using two different cell expression models we examined whether
mOATP2B1 also transports rosuvastatin. Rosuvastatin uptake was
increased 2.1- and 18.9-fold in HeLa cells transiently transfected
with mOATP2B1 and MDCKII-mOATP2B1 cells, respectively,
when compared with experimental control cells (Fig. 1G). Thus,
rosuvastatin is a substrate of mOATP2B1.
Characterization of Mice with Targeted Disruption of
mOATP2B1. In collaboration with the Knockout Mouse Consortium
(KOMP), we developed a mouse model with targeted disruption of
mOATP2B1 by introduction of a gene trap cassette within the Slco2b1
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and centrifuged for 10 minutes at 13,500 rpm. The resulting supernatant (20 ml)
was diluted with 125 ml of 0.1% formic acid in water (v/v). Standard curve samples
were created by spiking fexofenadine into blank human ethylenediaminetetraacetic
acid plasma (Bioreclamation IVT, Baltimore, MD) for subsequent processing
similar to plasma samples. Analytes were separated by liquid chromatography
(Agilent 1200; Agilent, San Clara, CA) using a Hypersil Gold C18 column (50 
3 mm, 5 mm; Thermo Fisher Scientific) following sample injection (75 ml for
plasma samples). A mobile phase of 0.1% v/v formic acid in water (A) and
acetonitrile (B) was used, with an elution gradient of 20% B from 0 to 1 minute,
20%–95% B from 1.0 to 4.5 minutes, 95% B from 4.50 to 5.25 minutes, 95%–20%
B from 5.25 to 5.80 minutes, and 20% B from 5.8 to 6.0 minutes, for a run time of
6 minutes and flow rate of 0.5 ml/min. The heated electrospray ionization
source of the triple quadrupole mass spectrometer (Thermo TSQ Vantage;
Thermo Fisher Scientific) was operated in positive mode (3500 V, 350C)
with collision energy set at 25 V. Additional ionization source conditions
used were as follows: 40 arbitrary units for sheath gas pressure, 15 arbitrary
units for auxiliary gas pressure, and 350C for capillary temperature.
Selected reaction monitoring for fexofenadine and d6-fexofenadine was
performed using mass-to-charge ratio (m/z) transitions 502.2 → 466.5 m/z
and 508.2 → 472.5 m/z, respectively. Both solutes had chromatographic
retention time of 3.2 minutes. Calibration curves were linear with plasma
fexofenadine concentrations between 0 and 3000 ng/ml. Interday assay
accuracy and precision were 3.2% and 10.0%, respectively. The lower limit
of quantitation was 2 ng/ml.
Rosuvastatin Assay. The concentration of rosuvastatin in plasma was
determined as previously reported (DeGorter et al., 2012). Briefly, plasma
samples were precipitated with acetonitrile containing d6-rosuvastatin as an
internal standard and centrifuged for 20 minutes at 14,000 rpm at 4C. The
supernatant was diluted 1:2 in 0.05% formic acid and analyzed by LC-MS/MS.
Solutes were separated by reverse-phase chromatography on a Hypersil GOLD
C18 column (50  3 mm, 5 mm; ThermoFisher Scientific) with 0.05% formic
acid/water and acetonitrile solvent gradient. After electrospray ionization,
mass spectrometric detection (TSQ Vantage) was performed in positive mode
with transitions 482.1 → 258.2 m/z for rosuvastatin and 488.0 → 264.3 m/z for
d6-rosuvastatin. Calibration curves were linear with plasma rosuvastatin
concentrations between 0 and 1000 ng/ml, while interday assay accuracy and
precision were 5.8% and 8.9%, respectively. The lower limit of quantitation
was 1 ng/ml.
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Fig. 1. Characterization of solute transport by mOATP2B1. (A) Expression and localization of mOATP2B1 (green) in MDCKII-control and MDCKII-mOATP2B1 cells
after stable transfection by immunofluorescence microscopy. Nuclei are stained with 49,6-diamidino-2-phenylindole (blue). (B) Immunoblot analysis of mOATP2B1
expression in MDCKII-control and MDCKII-mOATP2B1 cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the protein loading control. (C) Cellular
accumulation of [3H]-estrone sulfate (5 nM, N = 3), dehydroepiandrosterone sulfate (DHEAS) (1 mg/ml, N = 3), [3H]-bromosulfophthalein (5 nM, N = 4), and taurocholate
(2 mg/ml, N = 3) in MDCKII-control and MDCKII-mOATP2B1 after 10-minute incubation with compounds in Krebs-Henseleit buffer (KHB) at pH 6. Cellular uptake was
corrected for protein content per well and normalized to MDCKII-control (% control). (D) Cellular uptake of fexofenadine in HeLa cells transiently transfected with mock
empty vector/mOATP2B1 or MDCKII-control/MDCKII-mOATP2B1 cells. For HeLa experiments [3H]-fexofenadine (0.1 mM, N = 6) was applied, while for MDCKII
studies unlabeled fexofenadine (0.1 mM, N = 5) was applied to cells dissolved in KHB pH 6 for 30 or 10 minutes, respectively. For MDCKII cell experiments, cellular uptake
was corrected for protein content per well and normalized to MDCKII-control (% control). (E) Concentration-dependent fexofenadine uptake by mOATP2B1. Unlabeled
fexofenadine (0.1–300 mM) dissolved in KHB at pH 6 was applied to MDCKII-control and MDCKII-mOATP2B1 cells for 10 minutes. The mOATP2B1-mediated uptake
was calculated as the difference between uptake of mOATP2B1 and control cells with correction of protein content per well. Eadie-Hofstee (V/S vs. V) plot with the line
obtained by linear regression (V/S = 20.001037V + 0.4842, P = 0.025). (F) Inhibition of mOATP2B1 activity by erlotinib and fexofenadine. MDCKII-control and MDCKIImOATP2B1 cells were incubated with [3H]-bromosulfophthalein (5 nM, N = 3) and erlotinib (10 mM), fexofenadine (300 mM), or vehicle for 10 minutes in KHB at pH 6.
Cellular drug accumulation was corrected for protein content. The mOATP2B1-specific uptake was calculated as the difference between MDCKII-mOATP2B1
and MDCKII-control cells and normalized to MDCKII-control (% control). (G) Cellular uptake of rosuvastatin in HeLa cells transiently transfected with mOATP2B1 or
MDCKII-control/MDCKII-mOATP2B1 cells. For HeLa experiments [3H]-rosuvastatin (0.1 mM, N = 3) was applied to cells dissolved in Opti-MEM media, while for
MDCKII studies unlabeled rosuvastatin (0.1 mM, N = 5) was dissolved in KHB pH 6 for 30 or 10 minutes, respectively. For MDCKII cell experiments, cellular uptake was
corrected for protein content per well and normalized to MDCKII-control (% control). Results are shown as mean 6 S.E.M. **P , 0.01; ***P , 0.001; ****P , 0.0001 as
determined by unpaired, two-tailed Student’s t test.
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(Table 1). No differences in either Tmax or t1/2 among WT and KO groups
were observed. It should be noted that the estimates for t1/2 were less
reliable due to the limited sampling duration. The estimated bioavailability
was lower in KO versus WT mice (3.9% vs. 5.2%, respectively), but not
statistically significant. However, the values for AUC0–‘, which were used
to estimate bioavailability, were not particularly adequate given that the
sampling duration may not have been sufficient. These results demonstrate
that mOATP2B1 significantly affects the pharmacokinetics of oral but not
intravenous fexofenadine. That fexofenadine remained absorbed in KO
mice after oral administration, albeit at a significantly lower degree than in
WT mice, indicates transporters aside from mOATP2B1 may also be
responsible for fexofenadine absorption.
Impact of Fruit Juice Coadministration on Fexofenadine Oral
Pharmacokinetics in WT and KO Mice. The effects of coadministered GFJ or AJ on fexofenadine pharmacokinetics in WT and KO were
evaluated. In WT mice, GFJ reduced fexofenadine plasma concentrations (Fig. 3C), with significant reductions in Cmax and AUC0–last by
80% and 35%, respectively (Table 1). GFJ increased oral fexofenadine
Tmax in WT mice (Table 1). Oral AJ coadministration had greater effect
than GFJ on fexofenadine plasma concentrations in WT mice (Fig. 3C)
with lower Cmax and AUC0–last values of 88% and 70%, respectively, in
comparison with vehicle control (Table 1). These results demonstrate
that mice can recapitulate the fruit juice effect on oral fexofenadine
pharmacokinetics observed originally in humans (Dresser et al., 2002).
In KO mice, GFJ coadministration did not further reduce plasma
fexofenadine concentrations (Fig. 3D) or alter pharmacokinetic parameters when compared with vehicle control. However, in KO mice AJ
coadministration significantly reduced both fexofenadine Cmax and
AUC0–last values by 67% and 59%, respectively, when compared
with vehicle control (Table 1). Taken together, these findings suggest
that mOATP2B1 is largely responsible for altered oral fexofenadine
pharmacokinetics with GFJ coadministration. Given that AJ sustained additional reductions in systemic fexofenadine exposure in
KO mice, this indicates that the AJ effect on oral fexofenadine
pharmacokinetics in WT mice is dependent on both mOATP2B1 and
other transporters.

Fig. 2. Tissue gene expression in mOATP2B1 KO mice. (A) Liver,
kidney, small intestine mucosa, brain, and lung from adult male WT
and KO (N = 3–5) mice were harvested for OATP2B1 mRNA
expression by reverse-transcription quantitative polymerase chain
reaction (PCR). 18S RNA served as the gene normalization control.
Relative gene expression is presented in relation to liver using the
DDCt method. (B) Expression and localization of mOATP2B1
(green) in WT and KO mouse liver by immunofluorescence
microscopy. Nuclei are stained with 49,6-diamidino-2-phenylindole
(blue). (C) Immunoblot analysis of mOATP2B1 expression in WT
and KO mouse liver. Actin was used as the protein loading control.
(D) Drug transporter mRNA gene expression in small intestine,
liver, and kidney as determined by reverse-transcription quantitative
PCR. 18S RNA served as the gene normalization control. Relative
gene expression is presented in relation to each transporter for WT
mice using the DDCt method. Results are shown as mean 6 S.E.M.
N.D., not detected.
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locus. These KO mice were viable at birth, fertile, produced litters of
normal size, and appeared to have a normal life span. No differences
have been observed in the weight or growth rate of KO mice compared
with WT animals. Organs and tissues were normal in KO mice after
macroscopic examination and histologic analyses. Serum biochemistries
of the KO mice were unremarkable. In adult male KO mice, we observed
an absence of mOATP2B1 mRNA in tissues that highly express the
transporter in WT mice, namely, liver, kidney, small intestine, brain, and
lung (Fig. 2A). In WT mice, the expression of mOATP2B1 was greatest
in liver but undetectable in KO mice by immunofluorescence microscopy (Fig. 2B) and western blot (Fig. 2C). We next compared the
expression of potential fexofenadine and rosuvastatin transporters in
the small intestine, liver, and kidney of WT and KO mice to understand
whether there was compensation for loss of mOATP2B1 expression. Uptake
transporter expressions of mOATP1A1, mOATP1A4, mOATP1A5,
mOATP1A6, mOATP1B2, and mOCT1 mRNAs were not different
among WT and KO mice in these tissues (Fig. 2D). Moreover, the
mRNA expression of efflux transporters including Mrp2, Mdr1a, and
Bcrp were not different in the KO mice (Fig. 2D). Taken together,
we confirm successful targeted global disruption of mOATP2B1 in
the KO mouse model and report a lack of compensation of gene
expression by other transporters that may be relevant to fexofenadine
and rosuvastatin disposition.
Fexofenadine Pharmacokinetics in Mice with Targeted Disruption of OATP2B1. The plasma pharmacokinetic effects of fexofenadine
were determined in adult male WT and KO mice after intravenous
(1 mg/kg) and oral (1 mg/kg) administration. With intravenous administration, there was a lack of difference in the plasma concentrations of
fexofenadine between WT and KO mice (Fig. 3A). Pharmacokinetic
analyses showed the fexofenadine CLplasma, volume of distribution at
steady state, and t1/2 were similar among WT and KO mice (Table 1). Next,
fexofenadine was administered orally to WT and KO in PBS-vehicle at pH
3.5, a pH value similar to that measured in GFJ and AJ. We found
fexofenadine plasma concentrations were lower in KO compared with WT
mice with oral administration (Fig. 3B). In KO mice, Cmax and AUC0–last
were lower by 70% and 41%, respectively in comparison with WT mice
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Identification of Other Mouse Uptake Transporters for
Fexofenadine. We explored whether other transporters mediate
fexofenadine uptake as an explanation for the in vivo pharmacokinetic
findings. Indeed, previous studies demonstrate that rat OATP (rOATP)
1A1, rOAT1A4, rOATP1A5, and rOATP1B2 transport fexofenadine
(Cvetkovic et al., 1999; Dresser et al., 2002; Glaeser et al., 2007). Upon
heterologous expression of mouse OATP transporters in cultured cells,
we found that fexofenadine was a substrate of mOATP1A1, mOATP1A4,
and mOATP1A5, but not mOATP1A6 (Fig. 4A). Human OCT1 was
previously shown to transport fexofenadine (Glaeser et al., 2007), while
OCT3 and plasma membrane monoamine transporters are cation uptake
transporters expressed in enterocytes (Kekuda et al., 1998; Zhou et al.,

2007). Moreover, in vitro studies showed that plasma membrane monoamine transporter–mediated atenolol transport is inhibited by AJ flavonoids
(Mimura et al., 2017). Here, we found that mOCT1 transports fexofenadine
but this was not evident for mOCT3 or mPMAT (Fig. 4B). Since only
mOATP1A5 and mOCT1 are expressed in the small intestine (Fig. 2D), it
is possible that these transporters may also be involved in the oral
absorption of fexofenadine in mice.
Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of OATP2B1. With intravenous (1 mg/kg) (Fig. 5A) and oral
administration (10 mg/kg) (Fig. 5B) of rosuvastatin, there were no
significant differences in the plasma concentrations of rosuvastatin
between WT and KO mice. A lack of differences in the CLplasma and

TABLE 1
Fexofenadine pharmacokinetic parameters
WT Mice (1 mg/kg Fexofenadine)
Pharmacokinetic
Parameter

C0 (ng/ml)
Cmax (ng/ml)
Tmax (h)
AUC0–last (ng/ml 
h)
AUC0–‘ (ng/ml  h)
MRT (h)
t1/2 (h)
Vss (ml/kg)
CLplasma (ml/min per
kilogram)
F (%)

KO Mice (1 mg/kg Fexofenadine)

Intravenous Dose
(N = 4)

Oral Dose [PBSVehicle (N = 17)]

Oral Dose [GFJ
(N = 8)]

Oral Dose [AJ
(N = 9)]

Intravenous Dose
(N = 5)

Oral Dose [PBSVehicle (N = 14)]

Oral Dose [GFJ
(N = 7)]

Oral Dose [AJ
(N = 9)]

3000 6 630
—
—
634 6 79

—
46.0 6 48.3
0.25 6 0.36
27.2 6 14.4

—
9.3 6 3.9a
0.82 6 0.34a
17.7 6 8.2a

—
5.6 6 3.6a
0.64 6 0.93
8.1 6 3.8a

2620 6 2720
—
—
590 6 424

—
14.5 6 14.9b
0.32 6 0.27
16.1 6 11.2b

—
11.9 6 6.7
0.64 6 0.73
16.5 6 9.0

—
4.7 6 2.5c
0.84 6 0.73
6.6 6 2.9c

6
6
6
6
6

33.6 6 15.8
1.9 6 1.8
1.7 6 1.7
—
—

32.9 6 12.3
4.2 6 3.7
2.7 6 2.6
—
—

13.8 6 7.6a
3.3 6 1.1a
2.2 6 0.7
—
—

623
0.53
0.62
1151
33.9

6
6
6
6
6

24.1 6 12.6
2.8 6 1.5
1.8 6 1.1
—
—

22.7 6 12.5
3.3 6 1.8
2.2 6 1.4
—
—

7.7 6 1.8c
2.4 6 1.2
1.5 6 0.8
—
—

5.2 6 2.4

5.0 6 1.9

2.1 6 1.2a

3.9 6 2.0

3.7 6 2.0

1.2 6 0.3c

652
0.36
0.48
553
25.9

—

83
0.09
0.10
121
3.3

F, bioavailability; MRT, mean residence time; Vss, volume of distribution at steady state.
a
P , 0.05 compared with WT [1 mg/kg, orally (PBS-vehicle)].
b
P , 0.05 compared with WT [1 mg/kg, orally (PBS-vehicle)].
c
P , 0.05 compared with KO [1 mg/kg, orally (PBS-vehicle)].
—, not applicable.

—

425
0.16
0.06
542
13.8
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Fig. 3. Fexofenadine pharmacokinetics. (A) Fexofenadine (1 mg/kg
in saline) was administered by intravenous bolus injection to adult
male WT (N = 4) and KO (N = 5) mice. (B) Adult male WT
(N = 17) and KO (N = 14) mice were administered fexofenadine by
oral gavage [1 mg/kg in 200 ml PBS (pH 3.5)]. (C) Adult male WT
mice were administered fexofenadine (1 mg/kg) by oral gavage in
either 200 ml PBS at pH 3.5 (N = 17), 200 ml 4 concentrated GFJ
(N = 8), or 200 ml 4 concentrated AJ (N = 9). (D) Adult male KO
mice were administered fexofenadine (1 mg/kg) by oral gavage in
either 200 ml PBS at pH 3.5 (N = 14), 200 ml 4 concentrated GFJ
(N = 7), or 200 ml 4 concentrated AJ (N = 9). Plasma was obtained
at various time intervals by saphenous venous sampling and fexofenadine
concentrations were determined by LC-MS/MS. Plasma concentrations are shown as mean 6 S.E.M.
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volume of distribution at steady state between WT and KO mice after
intravenous administration (Table 2) indicates that the systemic
disposition of rosuvastatin is not appreciably affected by OATP2B1.
Furthermore, since the bioavailability of rosuvastatin was similar
between WT and KO mice (8.7% vs. 11.4%, respectively) (Table 2), this
result suggests that OATP2B1 does not significantly contribute to the
oral absorption of rosuvastatin in mice.

Discussion
On the basis of clinical pharmacokinetic fruit juice-drug interactions,
OATP2B1 has been implicated as a determinant of oral drug absorption
(Tamai and Nakanishi, 2013; Yu et al., 2017; McFeely et al., 2019).
Indeed, the International Transporter Consortium considers OATP2B1
as a transporter of emerging clinical importance, although at present it
does not recommend prospective testing with OATP2B1 during drug
development due to lack of sufficient clinical evidence (ZamekGliszczynski et al., 2018). A compelling case for OATP2B1 is
complicated by some examples of in vitro/clinical disconnect, as well as
recent reevaluation of the localization of the transporter in enterocytes
(Keiser et al., 2017; Oswald, 2019). Moreover, SLCO2B1 pharmacogenetic
studies of substrates such as fexofenadine have been conflicting and
inconsistent (Akamine et al., 2010; Imanaga et al., 2011). For rosuvastatin,

neither the common SLCO2B1 c.935G.A nor c.1457C.T genetic
polymorphisms have been associated with altered plasma concentrations (DeGorter et al., 2013; Kashihara et al., 2017). Therefore, there
is a need for additional studies and strategies to clarify the role of
OATP2B1 in drug disposition and response.
We developed a novel whole-body OATP2B1 knockout mouse
model to provide essential in vivo insights to connect results from
in vitro studies to clinical observations. OATP2B1 is conserved
throughout evolution, being found in worms, amphibians, fish, birds,
and mammals (Hagenbuch and Stieger, 2013). Importantly, it is the only
member of the OATP2B subfamily in all species that greatly simplifies
the study of OATP2B1 across different animal models. However, a
challenge of studying OATP function in rodents is the complex
orthology among the drug-transporting OATP1A/1B transporters.
For instance, humans have OATP1A2, while mice and rats express
OATP1A1, OATP1A4, OATP1A5, and OATP1A6. Furthermore, there
is a single rodent ortholog (OATP1B2) for the human OATP1B1 and
OATP1B3. In small intestinal enterocytes, humans express OATP2B1,
while rodents have OATP1A5 and OATP2B1. In hepatocytes, humans
express OATP1B1, OATP1B3, and OATP2B1, whereas rodents have a
larger complement of OATP1A1, OATP1A4, OATP1A6, OATP1B2,
and OATP2B1. We have found a lack of difference in OATP1A/1B
mRNA expression between WT and KO mice in intestine, liver, and

Fig. 5. Rosuvastatin pharmacokinetics. (A) Rosuvastatin (1 mg/kg
in saline) was administered by intravenous bolus injection to adult
male WT (N = 9) and KO (N = 8) mice. (B) Adult male WT (N = 6)
and KO (N = 6) mice were administered rosuvastatin by oral gavage
(10 mg/kg in 0.5% hydroxypropylmethylcellulose). Plasma was
obtained at various time intervals by saphenous venous sampling
and rosuvastatin concentrations were determined by LC-MS/MS.
Plasma concentrations are shown as mean 6 S.E.M.
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Fig. 4. Fexofenadine transport by mouse transporters.
(A) mOATP-mediated transport was determined in
HeLa cells transiently transfected with mock empty
vector, mOATP1A1 (N = 7), mOATP1A4 (N = 7), or
mOATP1A6 (N = 3). For other transporters, HEK293T
cells were transiently transfected with mock vector
control or mOATP1A5 (N = 3). (B) Organic cation
transporter–mediated transport of fexofenadine was evaluated in HeLa cells transiently transfected with mock empty
vector, mOCT1 (N = 4) or mOCT3 (N = 4). In other
experiments MDCKII-control and MDCKII-mPMAT
stable cells (N = 3) were used. [ 3 H]-fexofenadine
(0.1 mM) was applied to cells in Krebs-Henseleit buffer
at pH 6 (mOATPs) or pH 7.5 for other transporters for
10 minutes and cellular accumulation was determined.
For MDCKII cell experiments. Cellular uptake was
corrected for protein content per well and normalized
to MDCKII-control (% control). Results are shown as
mean 6 S.E.M. ***P , 0.001, ****P , 0.0001 as
determined by unpaired, two-tailed Student’s t test.
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TABLE 2
Rosuvastatin pharmacokinetic parameters
WT Mice

KO Mice

Pharmacokinetic Parameter

C0 (ng/ml)
Cmax (ng/ml)
Tmax (h)
AUC0–last (ng/ml  h)
AUC0–‘ (ng/ml  h)
MRT (h)
t1/2 (h)
Vss (ml/kg)
CLplasma (ml/min per kilogram)
F (%)

1 mg/kg, i.v. (N = 9)

10 mg/kg, Orally (N = 6)

1 mg/kg, i.v. (N = 8)

709 6 538
—
—
142 6 96
143 6 96
0.43 6 0.11
0.87 6 0.21
5081 6 4721
181 6 123
—

—
78 6 77
0.39 6 0.33
104 6 48
124 6 53
4.1 6 1.4
3.5 6 1.8
—
—
8.7 6 3.7

501 6 243
—
—
141 6 69
142 6 69
0.52 6 0.17
0.95 6 0.32
5138 6 4991
134 6 82
—

10 mg/kg, Orally (N = 6)

—
6 69
6 0.16
6 32
6 104
6 6.2
6 4.7
—
—
11.4 6 7.4

89
0.31
113
161
5.6
4.3

F, bioavailability; MRT, mean residence time; Vss, volume of distribution at steady state.
—, not applicable.

administration, plasma fexofenadine concentrations were significantly
increased owing to reduction in hepatic uptake and clearance (van de
Steeg et al., 2010). Studies in OATP1A4-deficient mice showed a lack of
effect on fexofenadine clearance, suggesting that the other hepatic
OATPs are important in elimination (Takano et al., 2018). The current
results showing a lack of pharmacokinetic differences after intravenous
dosing in OATP2B1 KO mice suggest that OATP2B1 does not
appreciably contribute to hepatic fexofenadine uptake and that indeed
OATP1A/1B transporters are the key determinants of liver disposition in
mice. In part by monitoring portal vein drug concentrations in Slco1a/
1b2/2 mice, it was concluded that the oral absorption of fexofenadine
was not dependent on OATP1A/1B transporters (van de Steeg et al., 2010),
which would include fexofenadine-transporting intestinal mOATP1A5.
Thus, our results suggest that mOATP2B1 partly contributed to the oral
absorption of fexofenadine in Slco1a/1b2/2 mice.
While we confirmed that rosuvastatin was a substrate for mOATP2B1
(as it is for human OATP2B1), neither oral nor intravenous rosuvastatin
plasma pharmacokinetics was altered by deficiency in murine
OATP2B1. However, it is clear that OATP1A/1B transporters are key
drivers of oral and intravenous rosuvastatin pharmacokinetics in mice, as
was revealed by significant increases in systemic exposures in the
Slco1a/1b2/2 model (Iusuf et al., 2013). Mouse OATP1A/1B strongly
affected rosuvastatin disposition by promoting hepatobiliary first-pass
and systemic elimination (Iusuf et al., 2013); a finding that was further
confirmed by examining uptake kinetics in isolated hepatocytes from
Slco1a/1b2/2 mice (Salphati et al., 2014). It would appear that at least
mOATP1B2 and mOATP1A4 are partly involved in overall hepatocyte
rosuvastatin uptake, as was exposed from pharmacokinetic studies in
single gene knockout mouse models (DeGorter et al., 2012; Takano
et al., 2018). Furthermore, studies with heterologous in vitro expression
in HeLa, CHO and HEK293 cells demonstrated that rosuvastatin was a
substrate for rOATP1A1, rOATP1A4, and rOATP1B2 (Ho et al., 2006;
Ishida et al., 2018). It was also noted that the intestinal absorption of
rosuvastatin was not impaired in Slco1a/1b2/2 mice (Iusuf et al., 2013).
This finding indicates that intestinal mOATP1A5 is not a major
determinant of rosuvastatin oral absorption in mice, although rosuvastatin
was shown to be a substrate for rOATP1A5 (Ho et al., 2006) and
mOATP1A5 (data not shown). Our current findings with KO mice
further clarify that intestinal mOATP2B1 is not involved in the rapid oral
absorption of rosuvastatin. Collectively, it seems likely that yet-to-bedetermined, non-OATP transporters promote oral rosuvastatin absorption in mice. In humans, OATP2B1 may be involved in oral rosuvastatin
absorption, as indicated in the clinical ronacalceret pharmacokinetic
interaction study (Johnson et al., 2017). However, a lack of significant
clinical grapefruit juice pharmacokinetic interaction (Kashihara et al., 2017)
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kidney (Fig. 2D). This suggests that the pharmacokinetic effects of
OATP2B1 gene disruption are without complication by compensatory
changes in OATP1A/1B. However, extrapolating the role of
OATP2B1 in the pharmacokinetics of drugs to humans, even with
the mouse KO model, requires caution due to different orthology and
tissue expressions of OATP1A/1B transporters, as well as potential
species differences in substrate specificity. In this regard, rodent
models with humanized transporter expression have been developed
and used to better understand the clinical importance of OATPs in
pharmacokinetics (van de Steeg et al., 2013; Higgins et al., 2014;
Salphati et al., 2014).
Despite the aforementioned complexities of OATPs among species, it
is remarkable that we observe clear pharmacokinetic differences for oral
fexofenadine in OATP2B1 KO mice with significant reduction in both
Cmax and AUC0–last but without differences in Tmax and t1/2 (Fig. 3B;
Table 1). The clearest differences in oral fexofenadine plasma concentrations between WT and KO mice were observed within the first
15 minutes after drug administration (Fig. 3B). Hence, due to practical
challenges of sampling, the rapid absorptive phase was not well characterized. After intravenous administration, we found that fexofenadine
pharmacokinetics was not different in KO mice (Fig. 3A). These results
persuasively indicate that OATP2B1 has presystemic effects on oral
fexofenadine disposition. It is also notable that the clinical interactions
between fruit juices and fexofenadine were recapitulated in WT mice,
including the finding that apple juice had greater effects than grapefruit
juice on systemic drug exposures (Fig. 3C). Because grapefruit juice did
not affect oral absorption of fexofenadine in KO mice (Fig. 3D), the
grapefruit juice effect in WT mice can be largely attributed to interactions
with OATP2B1. KO mice remain able to absorb fexofenadine, indicating
transporters aside from OATP2B1 may be involved and that these
transporters may also be targets of inhibition by apple juice. Our in vitro
results suggest that the other transporters facilitating fexofenadine oral
absorption in mice are mOATP1A5 and mOCT1 (Fig. 4). It is interesting
that rOATP1A5 and human OCT1 are inhibited by fruit juice flavonoids
(Dresser et al., 2002; Mimura et al., 2015). The possibility remains that
alterations in intestinal water movement caused by the high osmolarities
of the AJ and GFJ vehicles used in this study (2794 and 2464 mOsm/kg,
respectively) have affected fexofenadine absorption in a similar fashion
as was observed for the atenolol-AJ interaction in rats (Funai et al., 2019).
The current findings for fexofenadine in OATP2B1 KO mice should
be discussed in the context of studies with other OATP knockout
models. The pharmacokinetics of fexofenadine was previously examined in OATP1A/1B cluster knockout mice (Slco1a/1b2/2), which do
not express mOATP1A1, mOATP1A4, mOATP1A5, mOATP1A6, or
mOATP1B2 (van de Steeg et al., 2010). After intravenous and oral
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also implies that OATP2B1 is not a major determinant of oral
rosuvastatin absorption in humans.
As we demonstrate for fexofenadine, the expression of OATP2B1 in
the small intestine has pharmacokinetic significance. However, although
the liver highly expresses OATP2B1, a role for this transporter in hepatic
disposition appears minimal, at least for fexofenadine and rosuvastatin in
mice. Therefore, it is interesting that in humans the protein expression of
OATP2B1 can approach that of OATP1B1 (McFeely et al., 2019), but
OATP2B1 has not generally been considered a quantitative contributor
to overall hepatic rosuvastatin uptake in humans (Kitamura et al., 2008;
Bosgra et al., 2014). Recently, the tyrosine kinase inhibitor erlotinib was
found to be a substrate of OATP2B1 but not OATP1B1 or OATP1B3
(Bauer et al., 2018). Importantly, positron emission tomography studies
in humans with microdoses and therapeutic doses of [11C]-erlotinib
indicate that this compound may be a useful probe substrate to examine
the drug-drug interactions with liver OATP2B1 (Bauer et al., 2018).
Therefore, additional studies are necessary to determine the pharmacokinetic impact of OATP2B1 in the liver (as well as other tissues that
express the transporter such as the kidney and lung) and at the bloodbrain barrier.
In conclusion, we found that the pharmacokinetic effects of oral but
not intravenous fexofenadine are influenced by OATP2B1 in a wholebody knockout mouse model. Studies with fruit juice coadministration
provided additional evidence for a role of intestinal OATP2B1 in
determining fexofenadine bioavailability and as a target for food-drug
interactions. In addition, with the KO model, we demonstrate a lack of
in vivo impact for OATP2B1 in the disposition of another substrate,
rosuvastatin. It is expected that the KO mouse model will serve as a
valuable tool to understand the in vivo relevance of OATP2B1,
predict human drug disposition, and provide reasons for in vitro/
clinical disconnect.
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